PPARγ-deficient mice die at E9.5 due to placental abnormalities. The mechanism by which this occurs is unknown. We demonstrated that the new endocrine factor EG-VEGF controls the same processes as those described for PPARγ, suggesting potential regulation of EG-VEGF by PPARγ. EG-VEGF exerts its functions via prokineticin receptor 1 (PROKR1) and 2 (PROKR2). This study sought to investigate whether EG-VEGF mediates part of PPARγ effects on placental development. Three approaches were used i) in vitro, using human primary isolated cytotrophoblasts, and the extravillous trophoblast cell line (HTR-8/SVneo), ii) ex vivo, using human placental explants (n= 46 placentas), and iii) in vivo, using gravid wild type, PPARγ+/- and PPARγ-/- mice. Major processes of placental development, known to be controlled by PPARγ such as trophoblast proliferation, migration and invasion were assessed in the absence or presence of PROKR1 and PROKR2 antagonists. Both in human trophoblast cell and placental explants, we demonstrated that rosiglitazone, a PPARγ agonist, increased i) EG-VEGF secretion, ii) EG-VEGF and its receptors mRNA and protein expression, iii) placental vascularization, via PROKR1 and PROKR2, and iv) inhibited trophoblast migration and invasion via PROKR2. In the PPARγ-/- mouse placentas, EG-VEGF levels were significantly decreased, supporting an in vivo control of EG-VEGF/PROKRs system during pregnancy. The present data reveal EG-VEGF as a new mediator of PPARγ effects during pregnancy, and bring new insights into the fine mechanism of trophoblast invasion.

PPAR controls pregnancy outcome through activation of EG-VEGF: new insights into the mechanism of placental development

CONGIU, CENZO;ONNIS, VALENTINA;
2015

Abstract

PPARγ-deficient mice die at E9.5 due to placental abnormalities. The mechanism by which this occurs is unknown. We demonstrated that the new endocrine factor EG-VEGF controls the same processes as those described for PPARγ, suggesting potential regulation of EG-VEGF by PPARγ. EG-VEGF exerts its functions via prokineticin receptor 1 (PROKR1) and 2 (PROKR2). This study sought to investigate whether EG-VEGF mediates part of PPARγ effects on placental development. Three approaches were used i) in vitro, using human primary isolated cytotrophoblasts, and the extravillous trophoblast cell line (HTR-8/SVneo), ii) ex vivo, using human placental explants (n= 46 placentas), and iii) in vivo, using gravid wild type, PPARγ+/- and PPARγ-/- mice. Major processes of placental development, known to be controlled by PPARγ such as trophoblast proliferation, migration and invasion were assessed in the absence or presence of PROKR1 and PROKR2 antagonists. Both in human trophoblast cell and placental explants, we demonstrated that rosiglitazone, a PPARγ agonist, increased i) EG-VEGF secretion, ii) EG-VEGF and its receptors mRNA and protein expression, iii) placental vascularization, via PROKR1 and PROKR2, and iv) inhibited trophoblast migration and invasion via PROKR2. In the PPARγ-/- mouse placentas, EG-VEGF levels were significantly decreased, supporting an in vivo control of EG-VEGF/PROKRs system during pregnancy. The present data reveal EG-VEGF as a new mediator of PPARγ effects during pregnancy, and bring new insights into the fine mechanism of trophoblast invasion.
EG-VEGF, PPARgamma, pregnancy, placenta, trophoblast invasion
File in questo prodotto:
File Dimensione Formato  
american journal of physiology_2015.pdf

Solo gestori archivio

Descrizione: articolo principale
Tipologia: versione post-print
Dimensione 1.84 MB
Formato Adobe PDF
1.84 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11584/110842
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 19
social impact